Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Operations: 2011-2025

Historic Cash from Operations for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to -$1.9 million.

  • Aytu Biopharma's Cash from Operations rose 48.07% to -$618,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 42.33%. This contributed to the annual value of -$1.9 million for FY2025, which is 39.55% down from last year.
  • Aytu Biopharma's Cash from Operations amounted to -$1.9 million in FY2025, which was down 39.55% from -$1.4 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Cash from Operations registered a high of -$1.4 million during FY2024, and its lowest value of -$28.8 million during FY2022.
  • Moreover, its 3-year median value for Cash from Operations was -$1.9 million (2025), whereas its average is -$2.8 million.
  • Per our database at Business Quant, Aytu Biopharma's Cash from Operations soared by 82.21% in 2023 and then crashed by 39.55% in 2025.
  • Aytu Biopharma's Cash from Operations (Yearly) stood at -$26.0 million in 2021, then declined by 10.86% to -$28.8 million in 2022, then spiked by 82.21% to -$5.1 million in 2023, then surged by 72.94% to -$1.4 million in 2024, then plummeted by 39.55% to -$1.9 million in 2025.